Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay162018	Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies Dr. Michel Sadelain to Present Preclinical Data from iPSC-derived, TCR-less, CAR T-cell Collaboration at ASGCT 2018 SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular Read All »	View HTML
Toggle SummaryMay102018	Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress No Cancer Relapse Reported in Phase 1 PROTECT Study of ProTmune Anti-tumor Activity with No Dose-limiting Toxicities Observed in Initial Phase 1 Dose Escalation of FATE-NK100 in Advanced Solid and Liquid Tumors IND for Off-the-Shelf NK Cell Product FT500 Remains on Track for 2Q18 Submission Read All »	View HTML
Toggle SummaryMay032018	Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results SAN DIEGO , May 03, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryMay022018	Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference SAN DIEGO , May 02, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Chief Scientific Officer, will Read All »	View HTML
Toggle SummaryApr162018	Fate Therapeutics Announces Off-the-Shelf CAR T-cell Cancer Immunotherapy to be Featured at 2018 AACR Annual Meeting Press Program Off-the-Shelf CAR T-cell Product Candidate Designed to Target CD19-positive Tumor Cells and to Overcome Antigen Escape Manufacture from Master iPSC Line Enables Mass Production and Broad Accessibility without Patient Restriction AACR Press Program to Begin Today at 8:30 a.m. Read All »	View HTML
Toggle SummaryMar292018	Fate Therapeutics Announces Initial Clinical Data of FATE-NK100 for Recurrent Ovarian Cancer at the Innate Killer Summit 2018 Stable Disease with Tumor Shrinkage Reported in Subject 2 Following Single Dose of NK100 SAN DIEGO , March 29, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer Read All »	View HTML
Toggle SummaryMar192018	Fate Therapeutics Announces Additional Clinical Data from Phase 1 Stage of PROTECT Clinical Trial of ProTmune™ No Events of Cancer Relapse No ProTmune-related Serious Adverse Events Reported by Investigators SAN DIEGO , March 19, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for Read All »	View HTML
Toggle SummaryMar052018	Fate Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Operational Progress Initial Clinical Data of FATE-NK100 in Relapsed / Refractory AML Show Rapid Reduction of Leukemic Blasts in the Bone Marrow All Subjects in PROTECT Phase 1 Study of ProTmune Achieve Day 100 Relapse-free Survival Clinical-scale Production of FT500 Off-the-Shelf NK Cell Cancer Immunotherapy Initiated Read All »	View HTML
Toggle SummaryFeb272018	Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2017 Financial Results SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryFeb232018	Fate Therapeutics Announces Receipt of CIRM Grant for Clinical Translation of FT516 Off-the-Shelf Engineered NK Cell Cancer Immunotherapy $4.0 Million Awarded by CIRM to Support Advancement of First-of-Kind NK Cell Product Candidate derived from a Master Engineered iPSC Line SAN DIEGO , Feb. 23, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.